* Says OMS201 safe and well-tolerated
* Says study did not assess efficacy
Dec 29 (Reuters) - Omeros Corp (OMER.O) said its experimental drug for patients undergoing urological surgery showed the drug was safe and well-tolerated in an early/mid-stage trial.
The trial was designed to test the safety of OMS201 and see how higher concentrations of the drug were absorbed, the company said in a statement.
During the study, the drug -- a combination of an anti-inflammatory agent and a muscle relaxant -- was administered to patients undergoing ureteroscopy for removal of ureteral or renal stones.
Ureteroscopy is a procedure to examine the insides of the kidney and the tubes leading from the kidney to the bladder.
The trial also explored potential efficacy endpoints, but was not powered to assess efficacy, Omeros said.
The company’s shares, which have gained more than 30 percent over the last four months, closed at $8.02 Monday on the Nasdaq. (Reporting by Shailesh Kuber in Bangalore; Editing by Vyas Mohan)